01 Bioresorbable Scaffolds Use in Below-the-Knee Applications Bioresorbable vascular scaffolds are expanding from coronary treatment into below-the-knee applications for patients with peripheral artery disease. These devices provide temporary vessel support and gradually dissolve after the treated artery recovers. This shift broadens the clinical use of bioresorbable scaffolds in peripheral vascular treatment.
02 Shift toward Thinner-Strut Bioresorbable Scaffold Designs The bioresorbable vascular scaffold market analysis shows that new scaffold designs are using thinner struts to improve flexibility, deliverability, and placement within narrow or complex blood vessels. The reduced profile can also provide better vessel access while maintaining temporary structural support. This development improves the design and handling of bioresorbable vascular scaffolds.
01 Supply chain disruptions are expected to have a substantial impact on the bioresorbable vascular scaffold market share, as dependence on specialized resorbable polymers, drug-coating materials, radiopaque markers, precision components, and validated manufacturing and sterilization processes can create sourcing and production delays. The market is likely to follow a capacity-constrained recovery pattern, as limited qualified manufacturing capacity and lengthy validation and regulatory requirements can restrict scaffolding. The market is expected to grow at a CAGR of 8.43%, but supply chain constraints could approximately lower this by 0.5 percentage points, resulting in short-term growth of around 7.93%. As supply conditions normalize through improved availability of resorbable polymers and specialized components, broader qualified supplier networks, and more reliable medical-device logistics, bioresorbable vascular scaffold market growth is expected to gradually return to 8.43%.
01 The bioresorbable vascular scaffold market forecasts strategic investment activity driven by next-generation coronary and peripheral vascular scaffolds, regenerative vascular technologies, minimally invasive interventions, advanced biodegradable polymers, and clinical development of temporary vascular implants.In June 2025, Aortyx received ~USD15.7 million in Series A funding, supporting the development of Aortyx's bioresorbable vascular patch for aortic dissection, including advancement toward first-in-human readiness. The minimally invasive device uses biodegradable material as a temporary scaffold for tissue regeneration.
01 Preference for Temporary Vessel Support and Percutaneous Coronary Intervention Use Among Younger Patients Drives Market Demand The preference for temporary vessel support is driving the bioresorbable vascular scaffold market as these devices are designed to provide mechanical support during coronary healing and then gradually resorb, leaving no permanent scaffold in the treated vessel. This temporary approach supports interest in “leave-nothing-behind” coronary interventions by allowing the vessel to potentially recover more natural function after scaffold resorption.Use of percutaneous coronary intervention among younger patients is supporting demand for bioresorbable vascular scaffolds, particularly because younger patients have longer life expectancies and may potentially benefit from avoiding a permanent metallic implant. Clinical literature has identified younger patients with longer expected survival as a population in which the temporary nature of BRS may offer greater long-term rationale, although device safety and clinical outcomes remain important considerations.
01 Limited Scaffold Size Availability and Long-Term Clinical Evidence Gaps Restrain Market Expansion Limited availability of scaffold lengths and diameters can make device selection difficult for patients with varied coronary anatomy. This can restrict use of bioresorbable materials in vessels that do not match available device dimensions and reduce flexibility during vascular intervention.Limited long-term clinical evidence can make physicians more cautious about wider bioresorbable vascular scaffold (BVS) use across different patient groups and lesion types. Uncertainty around long-term vessel healing and outcomes can slow adoption of drug-eluting scaffold systems in cardiovascular treatment.
01 Development of Drug-Eluting Scaffold Platforms and Specialist Proctoring Services Offer Growth Opportunities The development of drug-eluting bioresorbable vascular scaffold (BVS) platforms can combine temporary vessel support with localized drug release within a single cardiovascular device. Manufacturers can differentiate products through drug-release profiles, scaffold materials, and treatment configurations for selected coronary interventions. This creates a specialized product opportunity within cardiovascular treatment.Bioresorbable scaffold training and proctoring services can support clinicians with device selection, implantation technique, and procedural optimization. Device manufacturers and specialist providers can offer hands-on training and case support for interventional cardiology teams. This creates a service opportunity alongside scaffold sales.
01 Variation in PCI Practices and Cardiovascular Device Procurement Fragmentation Hinders Market Growth Variation in percutaneous coronary intervention (PCI) practices across cardiac centers can create differences in patient selection, lesion treatment, and scaffold use. Such differences can make consistent integration of bioresorbable stents into routine vascular intervention more difficult across healthcare systems.Fragmented procurement processes can involve different hospital approvals, product evaluations, and purchasing requirements for cardiovascular devices. These differences can lengthen institutional onboarding and make broader adoption of bioresorbable materials less consistent across cardiac care networks.